The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to boost its cardiovascular pipeline.

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement of regulatory and sales milestones. The transaction, which could reach $3.1 billion in total value, is expected to close in the early part of 2025.

Acquisition includes abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients with atrial fibrillation and cancer-associated thrombosis.

(Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, to boost its cardiovascular business.

Novartis (NVS) has sealed a $3.1 billion deal to acquire clinical-stage biopharmaceutical company Anthos Therapeutics. The deal includes an

Novartis has agreed to buy Anthos Therapeutics from private equity firm Blackstone for $3.1 billion, adding a drug in late-stage clinical testing to prevent complications in patients with atrial fibrillation (AF).

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js

Swiss pharmaceutical company Novartis (SIX:NOVN) announced on Tuesday that it has entered into an agreement to purchase biopharma firm Anthos Therapeutics.

Swiss pharmaceutical giant Novartis said on Tuesday (Feb 11) it has agreed to acquire biopharma firm Anthos Therapeutics for up to US$3.1 billion. Read more at The Business Times.